Retatrutide vs Semaglutide: research-use prices, identity and FDA status (2026)
Retatrutide and Semaglutide are different research compounds, not substitutes for each other: Retatrutide is a single compound (C221H342N46O68); Semaglutide is a single compound (C187H291N45O59). Neither product has a current in-stock price right now. Retatrutide has no Drugs@FDA application; Semaglutide shares its active ingredient with an FDA-approved prescription medicine.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
Retatrutide vs Semaglutide: current prices and packages
| Compared property | Retatrutide | Semaglutide |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Compared package | 30mg | 10mg |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 48mg, 50mg, 60mg | 5mg, 10mg, 15mg, 20mg, 30mg, 50mg |
| Vendors with current prices | 0 | 0 |
| Form at this package | No listing | No listing |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Retatrutide | Semaglutide |
|---|---|---|
| Molecular formula | C221H342N46O68 | C187H291N45O59 |
| Molecular weight | 4731 g/mol | 4114 g/mol |
| Sequence | — | — |
| CAS Registry Number | — | 910463-68-2 |
| Registered clinical trials | 34 (11 active) · Phase 3: 14, Phase 2: 4, Phase 1: 15 | 34 (34 active) · Phase 4: 8, Phase 3: 12, Phase 2: 2 |
| Human intervention studies | 7 | 5 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | FDA-approved prescription medicine with this active ingredient: Ozempic, Rybelsus and Wegovy (NDA 209637, NDA 213051, NDA 213182, NDA 215256 and NDA 218316; checked October 7, 2026)MarketedOZEMPIC · NDA 209637 · 2017OZEMPIC / RYBELSUS · NDA 213051 · 2019RYBELSUS · NDA 213182 · 2020WEGOVY · NDA 215256 · 2021WEGOVY · NDA 218316 · 2025Research listings are not these medicines. |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Retatrutide
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024
Semaglutide
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism, 2022
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2021
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
Retatrutide
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.
No vendor has a current in-stock price for this package.
Retatrutide prices →Price history →Semaglutide
Semaglutide is a GLP-1 receptor agonist and the active substance in the EU-authorized prescription medicine Wegovy. Evidence and authorization attach to specified medicinal products and their studied use.
No vendor has a current in-stock price for this package.
Semaglutide prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →